As of now 11 investigator has remarkable research gives an account of Tandem Diabetes Care, Inc. (TNDM), as per the reports 3 examiners rate the stock "Purchase", 3 "Beat", 1 "Fail to meet expectations", 0 "Offer", while 4 "Hold".
The most as of late redesigned appraisals and value focuses from dealers issued for Tandem Diabetes Care, Inc. (TNDM) are incorporated underneath.
11/03/2016 – Broker: Piper Jaffray Rating: impartial emphasis
11/02/2016 – Broker: Deutsche Bank Rating: purchase New Target: 9 emphasis
11/02/2016 – Broker: Stifel Nicolaus Rating: hold New Target: 3.5 downsize
11/02/2016 – Broker: Robert W. Baird Rating: impartial New Target: 4 downsize
11/02/2016 – Broker: Feltl and Co. Rating: purchase minimize
09/27/2016 – Broker: B. Riley Rating: purchase New Target: 10 newcoverage
03/24/2016 – Broker: Bank of America Merrill Lynch Rating: fail to meet expectations minimize
10/21/2015 – Broker: William Blair Rating: showcase perform emphasis
05/01/2015 – Broker: Zacks Rating: purchase New Target: 15 redesign
02/25/2015 – Broker: Cowen Rating: beat New Target: 17 emphasis
11/04/2014 – Broker: Northcoast Research Rating: purchase newcoverage
10/27/2014 – Broker: Wedbush Rating: beat newcoverage
03/07/2014 – Broker: EVA Dimensions Rating: underweight newcoverage
The normal target value given to the organization from the most recent agent reports is 9.75
The stock expanded +10.42% (+0.25) amid the most recent days session, achieving 2.65 and approximately 332812 shares were purchased or sold by brokers. Pair Diabetes Care, Inc. (TNDM) has diminished by - 67.72% more than 12 months.
Couple Diabetes Care, Inc. is a therapeutic gadget organization. The Company is occupied with planning, creating and commercializing items for individuals with insulin-subordinate diabetes. The Company fabricates and offers three insulin pump items, which incorporate t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). Its innovation stage highlights Micro-Delivery Technology, a scaled down pumping component, which draws insulin from an adaptable sack inside the pump's cartridge as opposed to depending on a syringe and plunger system. It likewise includes a product, which is a distinctive shading touch screen and a smaller scale all inclusive serial transport (USB) association that backings both a rechargeable battery and transfers to t:connect Diabetes Management Application (t:connect), its custom cloud-based information administration application that gives show treatment administration information from the pump and upheld blood glucose meters.
The most as of late redesigned appraisals and value focuses from dealers issued for Tandem Diabetes Care, Inc. (TNDM) are incorporated underneath.
11/03/2016 – Broker: Piper Jaffray Rating: impartial emphasis
11/02/2016 – Broker: Deutsche Bank Rating: purchase New Target: 9 emphasis
11/02/2016 – Broker: Stifel Nicolaus Rating: hold New Target: 3.5 downsize
11/02/2016 – Broker: Robert W. Baird Rating: impartial New Target: 4 downsize
11/02/2016 – Broker: Feltl and Co. Rating: purchase minimize
09/27/2016 – Broker: B. Riley Rating: purchase New Target: 10 newcoverage
03/24/2016 – Broker: Bank of America Merrill Lynch Rating: fail to meet expectations minimize
10/21/2015 – Broker: William Blair Rating: showcase perform emphasis
05/01/2015 – Broker: Zacks Rating: purchase New Target: 15 redesign
02/25/2015 – Broker: Cowen Rating: beat New Target: 17 emphasis
11/04/2014 – Broker: Northcoast Research Rating: purchase newcoverage
10/27/2014 – Broker: Wedbush Rating: beat newcoverage
03/07/2014 – Broker: EVA Dimensions Rating: underweight newcoverage
The normal target value given to the organization from the most recent agent reports is 9.75
The stock expanded +10.42% (+0.25) amid the most recent days session, achieving 2.65 and approximately 332812 shares were purchased or sold by brokers. Pair Diabetes Care, Inc. (TNDM) has diminished by - 67.72% more than 12 months.
Couple Diabetes Care, Inc. is a therapeutic gadget organization. The Company is occupied with planning, creating and commercializing items for individuals with insulin-subordinate diabetes. The Company fabricates and offers three insulin pump items, which incorporate t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). Its innovation stage highlights Micro-Delivery Technology, a scaled down pumping component, which draws insulin from an adaptable sack inside the pump's cartridge as opposed to depending on a syringe and plunger system. It likewise includes a product, which is a distinctive shading touch screen and a smaller scale all inclusive serial transport (USB) association that backings both a rechargeable battery and transfers to t:connect Diabetes Management Application (t:connect), its custom cloud-based information administration application that gives show treatment administration information from the pump and upheld blood glucose meters.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.